Clinical Trials Logo

OSA clinical trials

View clinical trials related to OSA.

Filter by:

NCT ID: NCT06400615 Recruiting - OSA Clinical Trials

Study That Tests AD109 in Patients Taking GLP-1 Drugs

Start date: May 30, 2024
Phase: Phase 2
Study type: Interventional

Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide or Semaglutide

NCT ID: NCT06377332 Recruiting - COPD Clinical Trials

Biomarkers of Dementia in Chronic Sleep and Breathing Disorders

ORACLE
Start date: December 1, 2023
Phase:
Study type: Observational

Chronic obstructive pulmonary disease (COPD), obstructive sleep apnoea (OSA) and overlap syndrome are associated with obstructions in breathing and disturbed sleep. Chronic breathing disruptions and poor sleep may lead to cognitive impairment and brain changes linked with early neurodegenerative processes. As such, identifying early markers of cognitive impairment and dementia risk in individuals with chronic respiratory and sleep breathing disorders is crucial for understanding how these diseases may contribute to accelerated brain ageing. This study will comprehensively measure sleep, lung function, cognitive performance and blood-based markers of dementia risk and inflammation. The investigators will use innovative technologies to identify biomarkers of cognitive impairment and dementia risk in people with chronic sleep and breathing disorders. The investigators will also investigate the relationships between disrupted sleep and abnormal breathing and the brain. This research may also inform future early interventions to improve cognition and brain health in chronic sleep and respiratory disease.

NCT ID: NCT06320795 Recruiting - OSA Clinical Trials

Prospective Study for the Clinical Validation of the Soundi Wearable Medical Device

SOUNDI
Start date: November 22, 2023
Phase: N/A
Study type: Interventional

This is a pre-marketing, single-centre, prospective clinical trial with the aim of comparison the effectiveness and safety of the SOUNDI medical device compared to polysomnography in detecting parameters for the diagnosis of obstructive sleep apnea (OSA) syndrome in subjects with suspected diagnosis of sleep disorders.

NCT ID: NCT06265064 Completed - Obesity Clinical Trials

STOP-Bang Score and Factors Predicting Difficult Intubation for Prediction of Difficult Mask Ventilation in Obese Patients

Start date: July 11, 2022
Phase:
Study type: Observational [Patient Registry]

The goal of this prospective observational study is to test combination of STOP-Bang score and factors predicting difficult intubation can improve accuracy of prediction difficult mask ventilation in obese patients that undergoing to elective surgery under general anesthesia. The main question[s] it aims to answer are: - Can combination of STOP-Bang score and factors predicting difficult intubation improve accuracy of prediction difficult mask ventilation in obese patients? - Study about complication after endotracheal tube insertion in obese patients that undergoing to elective surgery under general anesthesia. Participants who undergoing to elective surgery under general anesthesia will - Routine preoperative evaluation and ask about STOP bang questions, evaluate neck circumference, Mallampati grade,Thyromental distance (That routine physical examination for anesthetic care pre-operation) - In operation room, patients will be inducted anesthesia by anesthesiologist (step routine for general anesthesia),observe difficult mask ventilation grading before intubate endotracheal tube and complication after endotracheal tube insertion. If there is a comparison group: Researchers will compare obese patients with/without high STOP bang score >=3 point plus factor predicting difficult intubation (Mallampati grade 3-4, Neck circumference > 42 cm, Thyromental distance < 6 cm)to prediction difficult mask ventilation

NCT ID: NCT06110962 Not yet recruiting - OSA Clinical Trials

Detecting Heart Rate, Respiration, and Sleep With the Sleeptracker-AI Under-mattress Monitor

Start date: May 20, 2024
Phase:
Study type: Observational

The objective of this study is to simultaneously acquire sleep and breathing data using the under-mattress Sleeptracker (The Sleeptracker-AI Monitor (Fullpower Technologies, California, USA) during routine PSGs in patients who attend the Woolcock Institute for undergoing investigation for possible obstructive sleep apnoea (OSA).

NCT ID: NCT06092710 Enrolling by invitation - Clinical trials for Obstructive Sleep Apnea

Predictability of OSA With a Subjective Screening Scale (OSASSS1)

OSASSS1
Start date: January 1, 2023
Phase:
Study type: Observational

the study aims to evaluate the accuracy correlation between subjective perception of the air flow through airways from patients and survey and/or polysomnography they spent, using a brief clinical protocol they answered with a manual therapist

NCT ID: NCT06091098 Recruiting - OSA Clinical Trials

Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA

Start date: March 27, 2024
Phase: N/A
Study type: Interventional

Obstructive sleep apnea (OSA) is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness, and quality of life. For years, a "classic" model of OSA has been used to describe the disorder, which fails to capture it's complexity. Recently, a model for OSA called drive-dependent OSA was discovered be more prevalent in the OSA population. The drive-dependent subgroup benefits exclusively from increased ventilation, increased dilator muscle activity, and reduced event risk when drive spontaneously rises. This study seeks to provide direct evidence that reducing the loss of drive prevents the loss of ventilation, pharyngeal muscle activity, and thus the onset of OSA respiratory events, specifically in "drive-dependent" but not "classic" OSA. This will be achieved using CO2 delivered at precise times during breaths in sleep to prevent loss of overall ventilatory drive.

NCT ID: NCT06091085 Recruiting - OSA Clinical Trials

Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA

Start date: January 31, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Obstructive sleep apnea (OSA) is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness, and quality of life. For years, a "classic" model of OSA has been used to describe the disorder, which fails to capture it's complexity. Recently, a model for OSA called drive-dependent OSA was discovered be more prevalent in the OSA population. This drive-dependent OSA is due to ventilation instability that occurs during respiratory events however these individuals have spontaneous increases in drive during respiratory events that stabilize their airway (i.e., via improving upper airway muscle activity) and reduce the risk of respiratory events in people with OSA. Therefore, by stabilizing the ventilatory drive, OSA should be treatable. Acetazolamide is a pharmacological ventilatory stimulant and has been previously shown to reduce OSA severity. As such in this study, the goal is to demonstrate acetazolamide improves OSA severity in 'drive-dependent' OSA people by improving drive-related pharyngeal obstructions compared to the 'classic' OSA people.

NCT ID: NCT06058052 Not yet recruiting - OSA Clinical Trials

Prevalence of OSA in Patients of ILD

Start date: October 20, 2023
Phase:
Study type: Observational [Patient Registry]

To evaluate the clinical predictors of OSA in patients with ILD

NCT ID: NCT06022679 Completed - OSA Clinical Trials

CBCT Analysis of the Craniofacial Architecture in Young, Non-overweight Apneic Adult Phenotype

ACAS-3D
Start date: April 1, 2022
Phase:
Study type: Observational

This prospective, controlled study will compare the 3D cephalometric analysis of bone and craniofacial soft tissues in young (18-35 years) non-overweight apneic adults phenotype between a test group (with AHI 15) and a control group (healthy subjects with AHI < 15).